Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an announcement.
Atomo Diagnostics has secured a A$416,000 purchase order for its HIV self-tests, to be supplied under the Mylan brand to an African country with funding from the Global Fund, a level of revenue the company deems material. This marks the second Global Fund–financed HIV self-test order it has received in early 2026, underscoring growing international demand for its HIV testing products and reinforcing Atomo’s positioning in the global rapid diagnostics market.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies patented, integrated rapid diagnostic test devices to the global diagnostics market. Its products are designed to simplify testing procedures, improve usability and enhance reliability for rapid point-of-care and at-home testing, with commercialised solutions and supply agreements in areas such as HIV, viral versus bacterial infection differentiation and early pregnancy detection.
Average Trading Volume: 1,115,499
Technical Sentiment Signal: Buy
Current Market Cap: A$31.6M
For detailed information about AT1 stock, go to TipRanks’ Stock Analysis page.